Hims (HIMS): FY26 Q1 earnings call, May 11, 2026

…believe it will also underpin our ability to enter emerging categories like peptides with a clinically rigorous, information-rich intake process that is designed to keep…

…successful customer outcomes. That doesn't exist in today's gray market, where the only peptide options are unregulated, inconsistent in quality, and rarely include clinical support.

…domestic supply chain, which we strengthened by investing in our own U.S.-based peptide facility last year, means that our customers can trust us to bring…

…are well-positioned to take advantage of opportunities for new offerings such as peptides as the regulatory landscape evolves. Trust remains the cornerstone of the Hims…

…that we received over the weekend were on the developing opportunity in peptides. This is a combination of questions from the Hims community as well…

…each patient's needs. Second, as we mentioned in the prepared remarks, our peptide manufacturing facility, which we acquired last year, gives us a fully verticalized…

…stay with us over time. We see momentum in newer specialties like testosterone, menopause, and labs, and our expanding selection of branded GLP-1 solutions is…

…circumstance. Then I think when you add on top of that the lab testing work that we've been doing, and the verticalization of that facilities,…

…This will extend our leadership position in consumer health across Australia, the U.K., Germany, Japan, and Canada by leveraging local expertise and existing industry relationships.

…first quarter of last year. International growth driven by our acquisitions of ZAVA and Livewell remained strong as revenue increased nearly tenfold from the first…

…to reach more people with innovative treatments and services. For example, our collaboration with Novo Nordisk shows what's possible when health innovators work together to…